Case report: prolonged durable clinical benefit and low toxicity from combination endocrine therapy in a patient with recurrent endometrial carcinoma

Case report: prolonged durable clinical benefit and low toxicity from combination endocrine therapy in a patient with recurrent endometrial carcinoma

BackgroundEndometrial carcinoma is the most common gynecologic cancer, with increasing incidence and mortality. Combination endocrine therapy comprised of tamoxifen and progestational agents has demonstrated promising results in treating recurrent disease. This case report describes the prolonged cl...

Full description

Bibliographic Details
Main Authors: Joyce M. Cheng, Stephanie Gaillard, Anna L. Beavis, Tullia Rushton, Amanda N. Fader
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Oncology
Subjects:
endometrial carcinoma
endometrioid
recurrence
endocrine therapy
tamoxifen
Progestational agent
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1249370/full

Similar Items

Similar Items